multiple species, including human, mouse, dog, chicken, and frog, in addition to rat, indicating that the kinases are conserved across species. ERK1 and ERK2 have been separated by chromatography on Mono Q. Stimulation by insulin increases the phosphorylation of both kinases on tyrosine residues, as assessed by immunoblotting with phosphotyrosine antibodies, and retards their elution from Mono Q. Each of these ERKs appears to account for a distinct peak of MBP kinase activity. The activity in each peak is diminished by incubation with either phosphatase 2a or CD45. Therefore, both enzymes have similar modes of regulation and appear to contribute to the growth factor-stimulated MAP2/MBP kinase activity measured in cell extracts.
Introduction
The molecular events triggered by extracellular signals that activate tyrosine phosphorylation have been the subject of intense study since Ushiro and Cohen (1980) discovered that the epidermal growth factor receptor had, in common with the transforming protein of Rous sarcoma virus, pp60v-src, protein-tyrosine kinase activity (Collett et al., 1980; Hunter and Sefton, 1980; Levinson et aL, 1980) . Receptors for insulin and many other growth factors also either contain intrinsic tyrosine kinase activity or activate tyrosine phosphorylation (Kasuga et al., 1982; Ek and Heldin, 1984; Maher, 1988; Veillette et al., 1988; Ullrich and Schlessinger, 1990) . Thus, it has been postulated that the effects of these factors are mediated by phosphorylation of specific downstream targets on tyrosine residues. Many of the phosphorylations that occur in response to insulin and other extracellular cues are not on tyrosine but on serine/threonine residues (e.g., those on ribosomal protein S6 kinases [Ballou et aL., 1988] , phosphatase 1 G binding protein [Dent et aL, 1990] , and acetyl coA-carboxylase [Borthwick et al., 1990] ). As a result, the cadre of protein-serine/ threonine kinases that are phosphorylated on tyrosine and activated in response to growthpromoting agents are key intermediates in these pathways.
Ray and Sturgill (1987) , Cicirelli et aL. (1 988) , and others (Hoshi et aL., 1988) have identified a microtubule-associated protein 2 (MAP2)1/myelin basic protein (MBP) kinase that appears to have the requisite properties; after insulin or nerve growth factor stimulation, it is rapidly activated and contains phosphate on tyrosine as well as on serine/threonine residues Boulton et aL., 1991 b) . Further, at least one potential target for this kinase, a ' Abbreviations: CHO, Chinese hamster ovary; DTT, dithiothreitol; EGTA, N,N,N''N'-tetraacetic acid; ERK, extracellular signal-regulated kinase; HEPES, N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid; MAP2, microtubule-associated protein-2; MBP, myelin basic protein; PCR, polymerase chain reaction; PMSF, phenylmethylsulfonyl fluoride; Tris, tris(hydroxymethyl)aminomethane. 357 ribosomal protein S6 kinase Gregory et al., 1989; , has been identified, suggesting that the MAP2/MBP kinase lies at an early step in a protein kinase cascade. The tyrosine-phosphorylated kinase is stimulated by a variety of growth factors and other extracellular signals, including insulin (Ray and Sturgill, 1987; Boulton et al., 1990a Boulton et al., , 1991 , epidermal growth factor (Hoshi et al., 1988; , nerve growth factor (Gomez et al., 1990; Miyasaka et al., 1990; Tsao et al., 1990; Boulton et al., 1991 b) and interaction of T cell surface receptors with presented antigens (Nel etaaL, 1990a) .
Chromatographic evidence from several laboratories (Cicirelli et aL, 1988; Hoshi, et al., 1988; Gomez et aL, 1990; Nel et al., 1990b; Boulton et al., 1991 b) suggests that the MAP2/MBP kinase activity may be derived from two or more distinct enzymes. This activity is believed to correspond to a group of 42-to 45-kDa spots originally identified 10 years ago by two-dimensional gel electrophoresis as growth factor-stimulated phosphotyrosinecontaining proteins (Martinez et al., 1982; Cooper et al., 1984; Rossomando et al., 1989) . The spots have not been assigned to either multiple unique but related kinases or to different phosphorylated or otherwise modified states of a single enzyme. Recently we have purified (Boulton et al., 1991 a) and cloned a rat MAP2/MBP kinase (Boulton et aL, 1990b ) that we named extracellular signal-regulated kinase 1 (ERK1). Using probes derived from ERK1, we have isolated cDNAs encoding two related kinases. Analysis of Southern blots with probes specific for each of the three kinases suggests the existence of even more members of this family (Boulton et al., 1991 b) . Of Results Characterization of antipeptide antibodies Antipeptide antibodies were generated to three peptides predicted by the ERK1 cDNA ( Figure  1 ): 1) a peptide corresponding to the C-terminal 16 amino acids, 2) a 23-residue peptide from protein kinase subdomain Xl (nomenclature of Hanks et aL, 1988) , and 3) a 16-residue peptide near the N-terminus just before the highly conserved GXGXXG of subdomain 1. All of the peptides are similar to sequences in ERK2 ( Figure  1 ). The C-terminal peptide elicited antibodies in two rabbits with distinct specificities. One antiserum (956) recognized a band the size of ERK1 (-43 kDa) both in partially purified preparations and in cell extracts (Figures 1-3) , almost exclusively. With antiserum 837, 25 ng of recombinant ERK2 was visible and bands the size of ERK2 (41 kDa) and ERK1 were detected not only in tissues extracts but also in partially purified MAP2/MBP kinase preparations (Figures 2 and  6 ). Antiserum 691, generated to the peptide from subdomain Xl, and antiserum 692, generated to the peptide near the N-terminus, also recognized the 43-and 41-kDa proteins in cell extracts (Figure 1 ). We conclude that the 43-kDa protein is ERK1. On the basis of the recognition of a protein of -41 kDa (the size predicted for ERK2 from its cDNA) by three antibodies made to different ERK1 peptides, the correspondence in the tissue distributions of the 41-kDa protein (Figure 2 ) with the ERK2 mRNA ( Figure 5 and Boulton et al., 1991 b) , the ability of the antibodies to recognize recombinant ERK2, and the ability of antibodies produced to recombinant ERK2 to recognize the same size protein in tissues and cell extracts (data not shown), we conclude that the 41 -kDa ERK protein detected in tissues and cell extracts is ERK2.
Antiserum 837 immunoprecipitated ERK1 but was unable to immunoprecipitate significant amounts of ERK2 under nondenaturing conditions; this conclusion is based on lack of activity recovered in immunoprecipitates of ERK2 (Figure 9 ), on the inability to recover a 41 -kDa 32p_ labeled band from labeled cells (Boulton et al., 1991 b; Robbins, Boulton, and Cobb, unpublished (Ferrell et al., 1991 (Figure 4 , e.g., testes pellet), as well as the smaller bands in kidney and intestine, is blocked by preincubation of the antibody with the peptide antigen, demonstrating the specificity of the interaction of the antibody with these bands (Figure 4 ). When these same tissues are blotted with antiserum 837, a band of a smaller size (-41 kDa) corresponding to ERK2 is also detected in all rat tissues examined. As with ERK1, ERK2 is present in greatest amounts in brain and spinal cord, but is barely detectable in liver, lung, muscle, and intestine. Like ERK1, ERK2 also appears to be predominantly soluble. Very little ERK2 is in the particulate fraction, notably in tissues such as testes, in which considerable ERK1 is associated with the particulate fraction. A few of the weakly reacting bands (especially in muscle), of similar size to ERK2, appear to interact nonspecifically, because their signal is not blocked by the peptide antigen (Figure 4) .
Using these antibody probes, we found no striking differences in the distributions of ERK1 and ERK2. The proteins are expressed in tissues roughly in proportion to the expression of their mRNAs ( Figure 5 and Boulton et al., 1990b; Boulton, et al., 1991 b ). Northern analysis of ERK1 and ERK2 demonstrated that the messages for these two enzymes are present in all tissues examined although in very low amounts in some tissues. ERK1 mRNA was most highly expressed in spinal cord and then brain, followed by intestine and lung. ERK2 mRNA was highly expressed in brain and then spinal cord, followed by muscle and heart. The parallel between mRNA and protein is weakest in intestine for ERK1 and in muscle for ERK2; in both cases less protein is present than expected. (Ferrell et al., 1991; Ferrell, unpublished data) was recognized by antiserum 837 but not by 956, suggesting that it was more similar to ERK2 than ERK1. This protein appeared to be intermediate between ERK1 and ERK2 in size. Subsequent cloning of the Xenopus pp42 demonstrates that it has greater sequence identity to ERK2 than ERK1, although it is very similar to both enzymes (Posada et a/, 1991) . Whether or not pp42 recVol. 2, May 1991 ognized in other contexts is also either identical to or most closely related to ERK2 has yet to be determined. Subcellular distribution of ERKs after insulin treatment Activation of MAP2/MBP kinase proceeds rapidly and begins to decay after 5 min in Rat 1 HIRc B cells (Figure 6 ). To determine whether the loss of stimulated kinase activity from supernatants with time was due to an activationdependent redistribution of ERK1 and/or ERK2 within the cell, we measured MAP2 kinase activity in soluble and particulate fractions from Rat 1 .HIRc B cells treated with insulin for different times. We also probed these fractions with antiserum 837. MAP2 kinase activity in the soluble fraction increased >8-fold with 5 min of exposure to insulin (Figure 6, upper panel), then slowly declined. A small (-50%) increase in MAP2 phosphorylating activity was found in the particulate fraction. This increase was less pronounced in other experiments. Immunoblotting these two subcellular fractions indicated that there was no correlation between the amount of stimulated activity and changes in the amount of ERK1 or ERK2 in the soluble fraction. There may have been a slight decrease in the soluble ERK1 and ERK2 recognized by the antibody after the cells were treated with insulin for 15 min. However, blottable protein mass was at the unstimulated level after 30 min. The particulate fraction contained predominantly ERK1, but both ERK1 and ERK2 protein appeared to increase slightly in the particulate fraction after 15 min of treatment with insulin. This increase might account in part for the small stimulation of particulate MAP2 kinase activity at this time. The amounts of ERK1 and ERK2 in this fraction returned to unstimulated levels by 30 min. There was little evidence for a significant redistribution of ERKs; therefore, loss of MAP2 kinase activity from the cytosol was not due to an activationinduced association of the enzyme with membrane-bound organelles, consistent with previous findings (Anderson et al., 1990; G6mez et al., 1990; Ahn et al., 1991) (Figure 7) . By the use of a shallow gradient, the two peaks can be separated by several fractions, with the first peak of stimulated kinase activity eluting in 364 fractions 33-38 (conductivities of 11.25-13 mS) and the second peak of stimulated activity eluting in fractions 45-51 (conductivities of 14-16 mS). There was little or no MBP kinase activity in the Mono Q profile of soluble proteins from unstimulated cells.
Immunoreactive ERK1 from insulin-treated cells, detected using a mixture of antisera 837 and 956, also eluted from the column in two peaks, the first in fractions 30-34 and the second in fractions 44-52 of the stimulated profile (Figure 7) . The second peak of ERK1 clearly comigrated with the second peak of stimulated kinase activity. However, the first peak of ERK1 eluted slightly earlier (fractions 30-34) than the first peak of protein kinase activity (fractions 33-38) but eluted in the same fractions as the protein (fractions 30-38) from the unstimulated cells. Thus, from this analysis alone, it was not clear whether ERK1 contributed to the first stimulated peak of kinase activity. Blotting similar Mono Q profiles with antiserum 956, the ERK1-selective antibody, showed that the 43-kDa band was the only immunoreactive protein in fractions 30-34 and 44-52, supporting the claim that the 43-kDa band is ERK1. In the profile from unstimulated cells all of the ERK1 eluted in fractions 30-36, indicating that on activation the portion of ERK1 corresponding to the second protein peak bound more tightly to Mono Q. Together the two peaks of ERK1 in the stimulated profile contained roughly the same amount of immunoreactive ERK1 as in the single peak in the unstimulated profile, suggesting that the majority of the immunoreactive protein is in these fractions and not elsewhere in the column profile.
ERK2 also eluted as one peak just ahead of ERK1 in the unstimulated profile (conductivities of 8-11.7 mS) in fractions 22-32, with fractions 28-30 having the most immunoreactive ERK2 (Figure 7 ). On stimulation of the cells with insulin, the elution of a portion of the ERK2 protein was altered, appearing in fractions 26-36 (8.5-13 mS), with the majority of immunoreactivity now in fractions 32-34. On the basis of its elution properties, ERK2 did not contribute to the second peak of kinase activity; however, it eluted with and, therefore, may have accounted for the majority of enzymatic activity in the first stimulated peak. Although it cannot be excluded that the MBP kinase activity in peak 1 is due to an unidentified enzyme, ERK2 is an MBP kinase based on data with the recombinant protein (Boulton et al., 1991 . I more, the fact that the ERK2 protein that is shifted comigrates with the peak of activity is additional evidence that this peak is due to active ERK2.
Immunoblotting of these fractions with antibodies to phosphotyrosine revealed that, in the insulin-stimulated profile, proteins that comigrated with the second peak of ERK1 protein (fractions [46] [47] [48] [49] [50] and the later eluting ERK2 protein (fractions 32-35) contained phosphotyrosine, suggesting that this modification is in part responsible for their retarded elution from Mono Q and the resulting increase in activity. two peaks of kinase activity. However, there was phosphotyrosine on a portion of ERK1 in the profile from stimulated cells (fraction 34) that overlapped in elution with the first peak of kinase activity, making it difficult to determine whether one or both ERKs contributed to this peak of activity. When the profile from unstimulated cells was blotted with antibodies to phosphotyrosine, a phosphotyrosine-containing, 43-kDa protein, which comigrated with the ERK1 standard, was present in fractions 32-34. These same fractions contained the majority of inactive ERK1 as detected with antisera 956 and 837. The basal phosphotyrosine on the 43-kDa protein may be a consequence of the overexpression of the insulin receptor (-1 06/cell) in the HIRc B line. There was very little or no phosphotyrosine detected in similar fractions from unstimulated PC12 cells (Boulton et al., 1991 b) .
To confirm the similarity in the sizes of the immunoreacting proteins, we compared the electrophoretic mobilities of the peak fractions from the Mono Q column on the same gel in duplicate and probed them with the ERK antibody, 691, and antiphosphotyrosine antibodies (Figure 8 ). Both immunoreactive ERK1 and ERK2 from peak 1 comigrated with the phosphotyrosine-containing proteins. ERK1 in peak 2 also comigrated with the phosphotyrosine-containing protein in that peak. In addition, ERKs 1 and 2 have been immunoprecipitated under denaturing conditions from insulin-treated and untreated cells and the immunoprecipitates have been immunoblotted with antibodies to phosphotyrosine. There is a significant increase in phosphotyrosine content in ERK1 and ERK2 from insulin-treated cells (Boulton et al., 1991 b) .
To determine which enzymes contributed to the two peaks of kinase activity, we immunoprecipitated ERK1 with antiserum 837 (which immunoprecipitates ERK1 but not ERK2) and precipitated ERK2 with an antibody to recombinant ERK2. The immunoprecipitated proteins from each of the two peaks of stimulated activity (fractions 35 and 47) were assayed for MBP kinase activity (Figure 9 ). Antiserum 837 immunoprecipitated very little activity from peak 1 but significant activity from peak 2. Furthermore, immunoprecipitation resulted in a loss of >850/o of the activity from peak 2 but little loss from peak 1 (data not shown). This finding confirmed that the second peak of activity was due to ERK1. Because no active ERK1 could be immunoprecipitated from peak 1, the MBP kinase activity was probably not due to activated ERK1. Antibody to recombinant ERK2 immunoprecipitated a small amount of MBP kinase activity from the first peak but none from the second peak. The efficiency of immunoprecipitation of this antibody is poor as determined from its ability to precipitate only a small fraction of autophosphorylated recombinant ERK2 protein.
Thus, it cannot be used to ascertain whether removal of ERK2 from peak 1 removes all MBP kinase activity.
Apparently only a portion of the ERK1 is activated by insulin under these conditions. The delayed elution of activated ERK1 may require further modifications, perhaps phosphorylation on serine/threonine and/or additional tyrosine residues (see Figure 10) . Because the first peak contained tyrosine-phosphorylated ERK1 but very little precipitable ERK1 activity, it may be that the ERK1 in this peak lacked serine/thre- onine phosphate. These other phosphorylations may activate the protein on stimulation of cells with insulin. Because ERK1 contained phosphotyrosine but was inactive in untreated cells, phosphorylation on serine/threonine, not tyrosine residues, may be limiting in the activation of ERK1 in Rat 1 cells. Altogether five observations lead us to suggest that the first peak of activity is derived from active ERK2. First, the later eluting ERK1 protein comigrates with the second peak of activity and, similarly, the later eluting portion of the ERK2 protein comigrates with the first peak of activity. Second, the first peak of ERK1 from stimulated cells does not exactly comigrate with the first peak of activity. In fact, the first peak of ERK1 protein in the stimulated profile and the peak of ERK1 protein in the unstimulated profile elute in nearly the same fractions. Third, phosphotyrosine is present in the later eluting fractions of ERK1 and ERK2, those that coelute with the peaks of activity. Fourth, on the basis of im- munoprecipitation, ERK1 does not contribute to the first peak of activity but some activity can be immunoprecipitated with ERK2 antibodies. Fifth, recombinant ERK2 has a substrate specificity similar to ERK1 (Boulton et al., 1991b) . Thus, on the basis of indirect evidence, the immune complex data, activity of recombinant ERK2, and the correlations of protein mass, phosphotyrosine content, and kinase activity noted above, it is likely that peak 1 represents the active form of ERK2. Proof will await antibodies that immunoprecipitate this kinase more efficiently.
Properties of ERK1 and ERK2
We characterized certain properties of the two peaks of activity to make an initial comparison of the two enzymes. The activity in peak 1, which is probably due to ERK2, phosphorylated MBP 2.8-fold better than MAP2, unlike recombinant ERK2, which phosphorylates both substrates at roughly equal rates. ERK1 (peak 2) phosphorylated MBP 2.2-fold better than MAP2 ( Figure  1 OA), consistent with data for the purified protein (Boulton et al., 1991 a). Ahn et al.
( 1 990) have found two peaks of EGF-stimulated MBP kinase, chromatographically similar to the insulin-stimulated peaks identified here, which contain proteins that immunoreact with our antibodies (Ahn et al., 1991; and data not shown) .
On the basis of chromatographic behavior and sizes of crossreacting bands, Peak E3 in that report is most likely ERK2 (our peak 1) and peak Vol. 2, May 1991 E4 is most likely ERK1 (our peak 2). Both peaks of MBP kinase activate an S6 peptide kinase , also demonstrating the similarity in substrate specificities of the two enzymes. An unusual property of ERK1 is its ability to use either Mg2+ or Mn2' as a source of divalent cation (Boulton et al., 1991 a) . Fractions containing ERK1 and ERK2 from the Mono Q profile were assayed in the presence of increasing concentrations of either Mg2+ or Mn2+. Like ERK1, the other peak of kinase activity had the ability to use either cation; the concentration dependence for both ions was virtually identical for both enzymes; maximum activity was exhibited at 10-15 mM ( Figure 1OB ). To compare the regulation of the two enzymes, each was treated with specific phosphatases. Both peaks of activity were inactivated by treatment with the serine/threonineselective phosphatase 2a (>85%; Figure 1 OC) and to a lesser extent with the tyrosine-specific phosphatase, CD45 (-70%; Figure 10C ).
This has been noted for other partially purified preparations of MAP2 kinases (Anderson et aL, 1990; Gomez et al., 1990; Ahn et al., 1991) . These results suggest that, for each enzyme, phosphorylation on both tyrosine and threonine and/or serine is required for full activity and that the phosphotyrosine-containing 41-kDa protein is the kinase that accounts for the MBP kinase activity in the first peak. On the basis of these three properties, substrate specificity, cation dependence, and regulation by multiple phosphorylations, these two peaks Phosphorylation of these ERKs on tyrosine is required, but not sufficient, for maximum activity. ERK1 appears to exist in stimulated cells in at least three forms, two of which are inactive: unphosphorylated (by which we mean lacking the activating phosphorylations, some of which must occur on serine/threonine residues) and inactive, tyrosine phosphorylated and inactive, and tyrosine phosphorylated and active, presumably due to the acquisition of critical serine/ threonine and perhaps additional tyrosine phosphorylations. In unstimulated Rat 1 HIRc B cells, but not in unstimulated PC12 cells, there is also a major component of inactive ERK1 that is tyrosine phosphorylated. Because a population of ERK1 is tyrosine phosphorylated but inactive, this form of ERK1 either lacks the serine/ threonine phosphate that activates it, has accumulated phosphate on tyrosines that are functionally silent, or both. Direct evidence that both ERK1 and ERK2 are regulated by phosphorylation on both tyrosine and serine/threonine comes from the demonstration that both are inactivated with phosphatases that remove either serine/threonine or tyrosine phosphates CELL REGULATION and the ERK1 immunoprecipitated from nerve growth factor-or insulin-treated cells contains phosphotyrosine, phosphothreonine, and phosphoserine (Boulton et al., 1991 b) .
A further implication of the results of immunoblotting the chromatographic profiles is that serine/threonine phosphorylation is the ratelimiting step in the activation of ERK1 and perhaps ERK2 by extracellular signals. Both insulin and nerve growth factor (Boulton et al., 1991 b) cause an increase in phosphotyrosine content of ERK1 protein that is not active. And, in fact, in Rat 1 HIRc B cells, some ERK1 contains phosphotyrosine in the absence of the stimulus. The large increase in MBP kinase activity induced in certain cell types by okadaic acid (Haystead et al., 1990) , an inhibitor of serinethreonine phosphatases (Haystead et al., 1989) 
Northern analysis
RNA isolation, Northern blotting, 32P-radiolabeling by polymerase chain reaction (PCR) and hybridization to labeled probes were performed as described in Maisonpierre et al. (1 990a). The DNA probe used for ERK2 was a 300-bp fragment from nucleotide 1122 to 1422 generated by amplification using specific primers and the cDNA as the template in a PCR reaction (Boulton et aL., 1991 b) . The ERK1 probe was as described in Boulton et aL. (1 990b).
Antibodies and immunoblotting
The peptide IFQETARFQPGAPEAP was synthesized by Lynn DeOgny and Clive Slaughter and consisted of one peptide species as determined by mass spectrometry. The other two peptides (see Figure 1) were the kind gifts of Natalie Vol. 2, May 1991 Ahn and Edwin Krebs (University of Washington, Seattle, WA) and were >90/o pure by HPLC analysis. The peptides, coupled to hemocyanin from Limulus polyphemus with glutaraldehyde, were used to immunize rabbits at 2-to 4-wk intervals. Immunospecificity was determined by preincubating the peptide antibodies with 250 (for 837) and 500 (for 956) ,uM peptide. Proteins immunoreacting with antisera 837 and 956 were detected using peroxidase-conjugated goat antirabbit IgG (Cappel, Durham, NC). Immunodection of proteins containing phosphotyrosine employed a rabbit polyclonal antibody described by Boulton et al. (1991 a) and immunoreacting proteins were visualized by the use of peroxidase-conjugated or alkaline phosphatase-conjugated secondary antibody. Prestained protein standards were from Sigma (St. Louis, MO). A polyclonal antiserum to recombinant ERK2 was the kind gift of Regeneron Pharmaceuticals (Tarrytown, NY) and will be described more fully elsewhere.
Immune complex kinase assay Aliquots (50 AI) from the Mono Q fractions were incubated with 4 Ml of antiserum 837, antibody to recombinant ERK2, or preimmune serum for 2 h on ice. Prewashed Pansorbin (Calbiochem, San Diego, CA) was then added for 1 h on ice. Immunoprecipitated protein was recovered by sedimentation in a microcentrifuge for 2 min. The material not precipitated was set aside for later assay. The immunoprecipitates were washed two times with 0.25 M Tris, pH 7.6, and 0.1 M NaCI and finally resuspended in 50 ul of 50 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES), pH 8. The immunoprecipitated kinase and the unprecipitated material were assayed by adding an equal volume of a 2x reaction mixture giving final concentrations of 50 MM [-y-32P]ATP (4400 cpm/pmol), 10 mM MgCI2, 1 mM dithiothreitol (DTT), 1 mM benzamidine, 0.3 mg/ml MBP, and 25 mM HEPES, pH 8.0, and incubated at 30°C for 30 min. The assays were terminated by removing the supernatants from the pelleted immune complexes and precipitating MBP in the assays with trichloroacetic acid. Chromatography Supernatants (-10 mg protein) were diluted threefold with water and applied to a Mono Q HR 5/5 column in 50 mM ,3-glycerol phosphate, pH 7.3, 0.1 mM sodium vanadate, 1 mM EGTA, and 0.1 MM pepstatin. Protein was eluted with a 60-ml gradient of 0-0.225 M NaCI in the buffer. One-milliliter fractions were collected. Fractions used for immunoblotting were precipitated with trichloroacetic acid as described in Boulton et al. (1991 a) .
Inactivation with phosphatases
A fraction from each of the two stimulated peaks of kinase activity from a Mono Q profile was exchanged into 25 mM HEPES, pH 7.5, 1 mM DTT, and 1 mM EDTA by chromatography on Sephadex G-50. Ten microliters of the exchanged kinases were incubated in 0.1 % ,B-mercaptoethanol, 7.7 mg/ml bovine serum albumin, and either 98 U/ml CD45 (kindly provided by E. Fischer and N. Tonks, University of Washington, Seattle, WA) or 13 ug/ml of the catalytic subunit of phosphatase 2A (kindly provided by M. Mumby, University of Texas Southwestern, Dallas, TX). The dephosphorylation reactions were performed for 60 min at 300C in the absence or presence of the appropriate phosphatase inhibitor; for CD45 1 mM sodium vanadate was added and for the reactions with phosphatase 2A 10 mM sodium phosphate was added. After incubation with the phosphatases, these amounts of inhibitors were added to stop the dephosphorylation reactions. The ability to phosphorylate MBP was then measured (Boulton et al., 1991a) in 50-id reactions containing an additional 5 mM sodium phosphate.
Other methods
Assay for MAP2/MBP kinase activity was described previously (Boulton et al., 1991 a) . ERK2 used as a standard was the recombinant protein expressed in E. cofi using the second in-frame methionine to initiate as described in (Boulton et al., 1991 b) . Other reagents and methods were as described (Boulton et al., 1991 a) .
